AMO Healon D Ophthalmic Viscosurgical Device Recall

Advanced Medical Optics, Inc. (AMO) has issued a recall for one lot of their AMO Healon D Ophthalmic Viscosurgical Device (OVD), 30 mg/mL fill size syringes, which are intended for use during various eye surgery procedures, such as cataract surgery, secondary intraocular lens implantation, corneal transplant surgery and glaucoma filtration surgery.

 
Testing of some OVD syringes showed endotoxin levels above the required limit, which could potentially cause eye inflammation or Toxic Anterior Segment Syndrome (TASS) in patients after surgery.
 
According to the FDA recall notice, some physicians have observed the inflammatory reaction in their patients at the one-day post-operative visit.

Most individuals who develop Toxic Anterior Segment Syndrome have symptoms develop within 12 to 24 hours after a generally uneventful eye surgery. Treatment of TASS generally involves intense topical corticosteroids, which most individuals respond rapidly to.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The syringes were distributed between September 1, 2008 and October 29, 2008. The recall only applies to one lot, labeled with Lot Number UD30654 AMO Healon D Opthalmic Viscosurgical Device.

AMO began sending letters to customers on October 30, 2008, but information about the recall was not posted on the FDA website until December 10, 2008. According to the FDA, the letters sent by AMO included a fax reply form which informed customers about the risk and asked them to stop using and remove all units of AMO Healon D OVD, Lot UD30654 from their inventory.

The action has been classified as a Class 1 recall, which is the most serious type of recall, reserved for situations where continued use of the product posts a reasonable probability of serious injury or death.

Advanced Medical Optics, Inc., which manufactures a number of different eye-related products, faced harsh criticism following a May 2007 contact lens solution recall involving their Complete MoisturePlus consumer product. That recall was issued after use of the contact lens solution was linked to an increased risk of a serious and potentially blinding eye infection known as Acanthamoeba keratitis.

Two months after that major recall, a CDC report suggested that only half of healthy contact lens users were aware of the recall, and less than a quarter were aware of which specific product was involved. Out of 151 individuals interviewed by the CDC, 15 people acknowledged using the Complete MoisturePlus solution during the month before the recall, and 12 were still using the product, unaware that Advanced Medical Optics had issued a recall.

AMO was criticized for not advertising the recall via television, radio or newspapers. They relied only on government bulletins, press releases and the media to inform the public, instead of notifying their customers directly.

Over 100 people have filed Acanthamoeba keratitis lawsuits against AMO as a result of the May 2007 Complete MoisturePlus recall.

2 Comments

  • TerryAugust 19, 2009 at 4:05 pm

    I cannot seem to find any current updates (August 19, 2009) on this AMO lawsuit from the Complete Moisture Plus Contact Lens Solution. My daughter has Acanthamoeba Keratitis and I want to know what is going on with this case. Any help?

  • AMO Healon D Recall: Cornea Transplant Chemical Agent Linked to Eye Problems : AboutLawsuits.comJanuary 5, 2009 at 4:18 pm

    [...] October 30, 2008, AMO originally issued a the eye surgery chemical agent recall for 4,439 units of Healon D, lot no. UD30654. The recall was issued after AMO receiving multiple [...]

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted today)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.